Literature DB >> 19435725

Rituximab fixed retreatment versus on-demand retreatment in refractory rheumatoid arthritis: comparison of two B cell depleting treatment strategies.

Y K O Teng, J Tekstra, F C Breedveld, F Lafeber, J W J Bijlsma, Jacob M van Laar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19435725     DOI： 10.1136/ard.2008.100438

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  10 in total

1.  Suppression of bone turnover by B-cell depletion in patients with rheumatoid arthritis.

Authors:  G Wheater; V E Hogan; Y K O Teng; J Tekstra; F P Lafeber; T W J Huizinga; J W J Bijlsma; R M Francis; S P Tuck; H K Datta; J M van Laar
Journal:  Osteoporos Int       Date:  2011-04-06       Impact factor: 4.507

2.  Rituximab-induced interleukin-15 reduction associated with clinical improvement in rheumatoid arthritis.

Authors:  César Díaz-Torné; M Angels Ortiz de Juana; Carme Geli; Elisabet Cantó; Ana Laiz; Héctor Corominas; Jordi Casademont; Josep M de Llobet; Cándido Juárez; César Díaz-López; Sílvia Vidal
Journal:  Immunology       Date:  2014-07       Impact factor: 7.397

3.  The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry: clues for the optimization of rituximab treatment strategies.

Authors:  Bert Vander Cruyssen; Patrick Durez; Rene Westhovens; Marie-Joelle Kaiser; Ilse Hoffman; Filip De Keyser
Journal:  Arthritis Res Ther       Date:  2010-09-10       Impact factor: 5.156

Review 4.  B cells in the pathogenesis and treatment of rheumatoid arthritis.

Authors:  Bethany Marston; Arumugam Palanichamy; Jennifer H Anolik
Journal:  Curr Opin Rheumatol       Date:  2010-05       Impact factor: 5.006

5.  Induction of long-term B-cell depletion in refractory rheumatoid arthritis patients preferentially affects autoreactive more than protective humoral immunity.

Authors:  Y K Onno Teng; Gillian Wheater; Vanessa E Hogan; Philip Stocks; E W Nivine Levarht; Tom W J Huizinga; Rene E M Toes; Jacob M van Laar
Journal:  Arthritis Res Ther       Date:  2012-03-12       Impact factor: 5.156

6.  Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID).

Authors:  Hans-Peter Tony; Gerd Burmester; Hendrik Schulze-Koops; Mathias Grunke; Joerg Henes; Ina Kötter; Judith Haas; Leonore Unger; Svjetlana Lovric; Marion Haubitz; Rebecca Fischer-Betz; Gamal Chehab; Andrea Rubbert-Roth; Christof Specker; Jutta Weinerth; Julia Holle; Ulf Müller-Ladner; Ramona König; Christoph Fiehn; Philip Burgwinkel; Klemens Budde; Helmut Sörensen; Michael Meurer; Martin Aringer; Bernd Kieseier; Cornelia Erfurt-Berge; Michael Sticherling; Roland Veelken; Ulf Ziemann; Frank Strutz; Praxis von Wussow; Florian M P Meier; Nico Hunzelmann; Enno Schmidt; Raoul Bergner; Andreas Schwarting; Rüdiger Eming; Michael Hertl; Rudolf Stadler; Michael Schwarz-Eywill; Siegfried Wassenberg; Martin Fleck; Claudia Metzler; Uwe Zettl; Jens Westphal; Stefan Heitmann; Anna L Herzog; Heinz Wiendl; Waltraud Jakob; Elvira Schmidt; Klaus Freivogel; Thomas Dörner
Journal:  Arthritis Res Ther       Date:  2011-05-13       Impact factor: 5.156

7.  Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.

Authors:  Isidoro González-Álvaro; Carmen Martínez-Fernández; Benito Dorantes-Calderón; Rosario García-Vicuña; Blanca Hernández-Cruz; Alicia Herrero-Ambrosio; Olatz Ibarra-Barrueta; Emilio Martín-Mola; Emilio Monte-Boquet; Alberto Morell-Baladrón; Raimon Sanmartí; Jesús Sanz-Sanz; Francisco Javier de Toro-Santos; Paloma Vela; José Andrés Román Ivorra; José Luis Poveda-Andrés; Santiago Muñoz-Fernández
Journal:  Rheumatology (Oxford)       Date:  2014-12-19       Impact factor: 7.580

Review 8.  Update on the use of rituximab for intractable rheumatoid arthritis.

Authors:  R John Looney
Journal:  Open Access Rheumatol       Date:  2009-06-26

9.  Summarizing current refractory disease definitions in rheumatoid arthritis and polyarticular juvenile idiopathic arthritis: systematic review.

Authors:  Hema Chaplin; Lewis Carpenter; Anni Raz; Elena Nikiphorou; Heidi Lempp; Sam Norton
Journal:  Rheumatology (Oxford)       Date:  2021-08-02       Impact factor: 7.580

10.  The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients: a post hoc analysis of three cohort studies.

Authors:  Nadia M T Roodenrijs; Maria J H de Hair; Gill Wheater; Mohsen Elshahaly; Janneke Tekstra; Y K Onno Teng; Floris P J G Lafeber; Ching Chang Hwang; Xinyu Liu; Eric H Sasso; Jacob M van Laar
Journal:  Arthritis Res Ther       Date:  2018-11-20       Impact factor: 5.156
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.